Literature DB >> 1797462

Prolonged intrauterine contraception: a seven-year randomized study of the levonorgestrel 20 mcg/day (LNg 20) and the Copper T380 Ag IUDS.

I Sivin1, J Stern, E Coutinho, C E Mattos, S el Mahgoub, S Diaz, M Pavez, F Alvarez, V Brache, F Thevenin.   

Abstract

A levonorgestrel-releasing IUD and the Copper T 380Ag IUD were in randomized comparison for seven years in five clinics. In two other clinics the randomized study was truncated at five years, but use of the Copper T continued. No pregnancies occurred to users of either device in years 6 and 7. Cumulative pregnancy rates were 1.1 per 100 at seven years for the steroid-releasing and 1.4 per 100 for the copper-releasing IUDs. Cumulative rates of PID did not differ between devices. Infection rates appeared to be lowest during the sixth and seventh years of the study. Termination attributable to amenorrhea was the principal contributor to differences in cumulative continuation rates between devices. At the five clinics that carried the comparative study to seven years, cumulative continuation rates were 24.9 per 100 for LNg20 IUD users and 29.4 per 100 for TCu 380Ag users. Women who used either method for periods of five to seven years experienced, on average, marked to mild increases in hemoglobin as compared with levels at admission. The Copper T380 family and the LNg20 IUDs represent the most effective reversible contraceptive methods yet studied in long-term randomized trials.

Entities:  

Keywords:  Adnexitis; Biology; Comparative Studies; Contraception; Contraception Continuation; Contraception Termination--statistics; Contraceptive Effectiveness; Contraceptive Methods; Contraceptive Usage; Demographic Factors; Diseases; Family Planning; Fertility; Fertility Measurements; Hemic System; Hemoglobin Level--statistics; Incidence; Infections; Iud; Iud, Copper Releasing; Iud, Hormone Releasing; Measurement; Method Acceptability; Pelvic Inflammatory Disease; Physiology; Population; Population Dynamics; Pregnancy Rate--statistics; Reproductive Tract Infections; Research Methodology; Studies

Mesh:

Substances:

Year:  1991        PMID: 1797462     DOI: 10.1016/0010-7824(91)90149-a

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  25 in total

Review 1.  Recent developments in hormonal contraception.

Authors:  Eleanor A Drey; Philip D Darney
Journal:  Rev Endocr Metab Disord       Date:  2002-09       Impact factor: 6.514

Review 2.  As the world grows: contraception in the 21st century.

Authors:  R John Aitken; Mark A Baker; Gustavo F Doncel; Martin M Matzuk; Christine K Mauck; Michael J K Harper
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

3.  Levonorgestrel intrauterine device can be left in place for five years.

Authors:  M Harrison-Woolrych; J M Raine
Journal:  BMJ       Date:  1998-07-11

4.  Data support extended use of levonorgestrel intrauterine systems.

Authors:  D Mansour; J Guillebaud
Journal:  BMJ       Date:  1998-05-30

Review 5.  A risk-benefit assessment of the levonorgestrel-releasing intrauterine system.

Authors:  F Sturridge; J Guillebaud
Journal:  Drug Saf       Date:  1996-12       Impact factor: 5.606

Review 6.  Abnormal Uterine Bleeding in Young Women with Blood Disorders.

Authors:  Kathryn E Dickerson; Neethu M Menon; Ayesha Zia
Journal:  Pediatr Clin North Am       Date:  2018-06       Impact factor: 3.278

Review 7.  Medical treatment of uterine leiomyoma.

Authors:  Mohamed Sabry; Ayman Al-Hendy
Journal:  Reprod Sci       Date:  2012-02-28       Impact factor: 3.060

8.  Long-term safety, efficacy, and patient acceptability of the intrauterine Copper T-380A contraceptive device.

Authors:  Bliss Kaneshiro; Tod Aeby
Journal:  Int J Womens Health       Date:  2010-08-09

9.  Review of the safety, efficacy and patient acceptability of the levonorgestrel-releasing intrauterine system.

Authors:  Chandra Kailasam; David Cahill
Journal:  Patient Prefer Adherence       Date:  2008-02-02       Impact factor: 2.711

10.  The levonorgestrel-releasing intrauterine system: Safety, efficacy, and patient acceptability.

Authors:  Megan N Beatty; Paul D Blumenthal
Journal:  Ther Clin Risk Manag       Date:  2009-08-03       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.